Sumitomo Pharma Co., Ltd.
Stock Price Chart
2026/03/02 UpdatedPrice Trend
2026/03/02 UpdatedPrice & Trading Details
2026/03/02 UpdatedPRICE
TRADING
Analyst Recommendations 7 analysts
Updated 2026/03/01Shareholder Composition
Updated 2026/03/01Top Mutual Funds / ETFs
Updated 2026/03/01Major Holders
Updated 2026/03/01| Fund Name | Ownership | Shares | Change |
|---|---|---|---|
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
2.4M | +1.24% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
1.6M | +2.17% | |
|
iShares Trust-iShares Core MSCI EAFE ETF
|
1.2M | 0.00% | |
|
iShares Trust-iShares MSCI EAFE Small-Cap ETF
|
674.4K | +1.03% | |
|
Old Westbury Funds Inc-Old Westbury Small & Mid Cap Strategies Fund
|
654.0K | +55.71% | |
|
OBERWEIS FUNDS-Oberweis International Opportunities Fund
|
517.4K | -2.60% |
| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
Legato Capital Management LLC
|
41.1K | +52.50% |
Dividend History
Updated 2026/03/01| Year | Dividend | Change |
|---|---|---|
| 2023 | ¥7 | -75.0% |
| 2022 | ¥28 | 0.0% |
| 2021 | ¥28 | 0.0% |
| 2020 | ¥28 | -20.0% |
| 2019 | ¥35 | - |
Financial Performance
2026/03/01 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥560,035M | ¥555,544M | ¥314,558M | ¥398,832M |
| Gross Profit | ¥402,908M | ¥376,625M | ¥187,981M | ¥245,395M |
| Operating Income | ¥60,234M | -¥76,979M | -¥354,836M | ¥29,709M |
| Pretax Income | ¥86,011M | -¥44,761M | -¥318,837M | ¥31,111M |
| Net Income | ¥56,413M | -¥74,512M | -¥314,969M | ¥23,634M |
| EPS | ¥141.99 | -¥187.55 | -¥792.79 | ¥59.49 |
| Operating Margin | 10.76% | -13.86% | -112.80% | 7.45% |
| Balance Sheet | ||||
| Total Assets | ¥1,308,007M | ¥1,134,742M | ¥907,506M | ¥742,604M |
| Total Equity | ¥607,888M | ¥406,749M | ¥156,063M | ¥169,479M |
| Total Liabilities | ¥700,119M | ¥727,993M | ¥751,443M | ¥573,125M |
| Cash | ¥202,984M | ¥143,478M | ¥29,047M | ¥23,116M |
| Interest-bearing Debt | ¥269,048M | ¥334,716M | ¥418,884M | ¥305,422M |
| Equity Ratio | 46.47% | 35.85% | 17.20% | 22.82% |
| D/E Ratio | 0.44 | 0.82 | 2.68 | 1.80 |
| Cash Flow | ||||
| Operating CF | ¥31,239M | ¥11,937M | -¥241,893M | ¥16,500M |
| Investing CF | -¥18,278M | ¥52,419M | ¥33,036M | ¥99,754M |
| Financing CF | -¥21,426M | -¥146,817M | ¥77,851M | -¥108,836M |
| Free CF | ¥17,745M | -¥805M | -¥257,623M | ¥3,470M |
| Efficiency | ||||
| ROE | 9.28% | -18.32% | -201.82% | 13.95% |
| ROA | 4.31% | -6.57% | -34.71% | 3.18% |
Latest IR Information
-
Notice Regarding Registration of Issuance Concerning New Share Issuance
Sumitomo Pharma has registered the issuance of new shares with an upper limit of 60,000,000 shares and 140 billion yen, planning to secure funds to promote the growth strategy 'Boost 2028.'
Read more -
Formulation of Boost 2028 ― Accelerating the Strong Sumitomo Pharma ―
Sumitomo Pharma has formulated the growth strategy 'Boost 2028' covering fiscal years 2026 to 2028, aiming for over 350 billion yen in sales from Orgovix and Gemtesa, ROE above 10%, and equity ratio over 50% by fiscal 2028.
Read more -
Boost 2028: Accelerating a Strong Sumitomo Pharma
Sumitomo Pharma forecasts core sales of approximately 260 billion yen, core operating income of approximately 43 billion yen, and free cash flow of approximately 47 billion yen for FY2025, announcing a growth strategy targeting core product sales of 250 billion...
Read more -
Notice Regarding Revision of Earnings Guidance for Fiscal Year Ending March 2026
Revised the revenue for the fiscal year ending March 2026 to 449.0 billion yen (4.7% increase from previous forecast), operating income to 108.0 billion yen (10.2% increase), and net income attributable to owners of parent to 102.0 billion yen (10.9%...
Read more
Latest News (5 items)
-
Average Analyst Rating: hold
Average Target Price: ¥2,282
Rating Score: 2.71 (Based on 7 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
Sumitomo Pharma Co., Ltd. Manufactures, purchases, and sells pharmaceutical products for medical treatment in Japan, North America, and Asia. It offers therapeutic agents for parkinson's disease, type 2 diabetes, advanced prostate cancer, uterine fibroids and endometriosis, overactive bladder, and pediatric congenital athymia. The company also provides atypical antipsychotic, generic products, antiepileptic, atypical antipsychotic, and carbapenem antibiotic. In addition, it offers veterinary medicines, medical devices, etc. The company has collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was incorporated in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.
